Related Experiment Video
Updated: May 17, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Targeting FOXM1 in cancer
Marianna Halasi1, Andrei L Gartel1
1Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States of America.
Abstract:
Oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers. In addition, FOXM1 has been implicated in cell migration, invasion, angiogenesis and metastasis. The important role of FOXM1 in cancer affirms its significance for therapeutic intervention. Current data suggest that targeting FOXM1 in mono- or combination therapy may have promising therapeutic benefits for the treatment of cancer. However, challenges with the delivery of anti-FOXM1 siRNA to tumors and the absence of small molecules, which specifically inhibit FOXM1, are delaying the development of FOXM1 inhibitors as feasible anticancer drugs. In this review, we describe and summarize the efforts that have been made to target FOXM1 in cancer and the consequences of FOXM1 suppression in human cancer cells.
Insights
Targeting the oncogenic transcription factor FOXM1 shows promise for cancer therapy. However, challenges in delivery and specific inhibitors hinder the development of FOXM1-targeted anticancer drugs.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The transcription factor FOXM1 is overexpressed in many human cancers.
- FOXM1 plays a role in cancer progression, including cell migration, invasion, angiogenesis, and metastasis.
Purpose of the Study:
- To review and summarize efforts to target FOXM1 in cancer.
- To discuss the consequences of suppressing FOXM1 in human cancer cells.
Main Methods:
- Literature review of studies targeting FOXM1.
- Analysis of the impact of FOXM1 suppression on cancer cells.
Main Results:
- FOXM1 is a significant therapeutic target in oncology.
- Targeting FOXM1, alone or in combination therapy, may offer therapeutic benefits.
- Challenges include siRNA delivery to tumors and lack of specific small molecule inhibitors.
Conclusions:
- FOXM1 is a crucial factor in cancer development and progression.
- Developing effective FOXM1 inhibitors is essential for advancing cancer therapy.
- Further research is needed to overcome current delivery and specificity challenges.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic cells are...